非布索坦对痛风患者血清细胞因子IL-1β、TNF-α及COX-2的影响

摘要

Objective To observe the effect of febuxostat on IL-1β, TNF-αand COX-2 in gout patients.Methods 82 patients with gout in our hospital from August 2015 to August 2016 were divided into the groups of 40 mg/day of febuxostat and 80 mg/day of febuxostat randomly, 41 cases respectively.Select the same period in our hospital health examination of 41 cases.The levels of serum uric acid were measured before and after one week, two weeks and four weeks after treatment.Serum levels of IL-1β, TNF-αand IL-1βin serum were measured by enzyme-linked immunosorbent assay (ELISA) COX-2 levels.Results The levels of serum uric acid in the group of 40 mg/day vs 80 mg/day of febuxostat were (570.4 ±70.5) μmol/L and (572.8 ±71.2) μmol/L, significantly higher than the normal group (296.5 ±9.7) μmol/L (P<0.05), serum uric acid level decreased gradually with the time of administration, and the serum uric acid levels of the two dosages of fosobutamol at one,two,four weeks were significantly lower than before treatment (P<0.05), but not to below the normal level.The IL-1βof 40 mg/day and 80 mg/day of febuxostat was (40.5 ±6.8) pg/mL and (41.7 ±7.2) pg/mL, COX-2 were (15.5 ±1.7) pg/mL and (15.8 ±1.8) pg/mL respectively, significantly higher than the normal group (8.8 ± 1.7) pg/mL (P<0.05), The expression of IL-1βwas significantly decreased at the second week of IL-1βdecreasing as the time of IL-1βdecreased gradually (P<0.05); TNF-αin 40 mg/day group and 80 mg/day group was significantly lower than that before treatrment (P<0.05), but not to below the normal level.Conclusion Febuxostat can significantly reduce serum uric acid levels in patients with gout, and may reduce IL-1β, TNF-αand COX-2 and other cytokine levels.%目的 观察非布索坦对痛风患者血清细胞因子IL-1β、TNF-α及COX-2的影响.方法 选取2015年8月~2016年8月于山东大学齐鲁医院就诊的痛风患者82例,随机分为非布索坦40 mg/d组和非布索坦80 mg/d组,各41例,选取同期于本院体检的健康人41例,分别于治疗前,治疗1、2、4 w测定患者血清尿酸水平,采用ELISA法检测血清中细胞因子IL-1β、TNF-α及COX-2的水平.结果 治疗前,非布索坦40 mg/d组和非布索坦80 mg/d组血清尿酸水平分别为(570.4±70.5)μmol/L和(572.8±71.2)μmol/L,显著高于正常组的(296.5±9.7)μmol/L(P<0.05),血清尿酸水平随着给药时间逐渐下降,治疗后1、2、4 w,2个治疗组血清尿酸均显著低于治疗前(P<0.05);非布索坦40 mg/d组和非布索坦80 mg/d组IL-1β分别为(40.5±6.8)pg/mL和(41.7±7.2)pg/mL,COX-2分别为(15.5±1.7)pg/mL和(15.8±1.8)pg/mL,均显著高于正常组的(15.8±2.7)pg/mL和(8.8±1.7)pg/mL(P<0.05);IL-1β第2周开始显著下降,COX-2第1周开始显著下降(P<0.05);非布索坦40 mg/d组和非布索坦80 mg/d组治疗1、2、4周TNF-α水平均显著低于治疗前(P<0.05).结论 非布索坦可以显著降低痛风患者血清尿酸水平,可能和降低IL-1β、TNF-α及COX-2等细胞因子水平有关.